Article Text

Download PDFPDF
Cryoablation following neoadjuvant tyrosine kinase inhibitor as treatment of a T1a renal clear cell carcinoma in a patient with a solitary kidney
  1. Marie Zöga Diederichsen1,
  2. Kathrine Synne Weile2,
  3. Cecilie Bekker Christiansen2 and
  4. Pia Iben Pietersen1,3
  1. 1Department of Radiology, Odense University Hospital, Odense, Syddanmark, Denmark
  2. 2Department of Oncology, Odense University Hospital, Odense, Syddanmark, Denmark
  3. 3Research and Innovation Unit of Radiology - UNIFY, Department of Clinical Research, University of Southern Denmark, Odense, Syddanmark, Denmark
  1. Correspondence to Dr Marie Zöga Diederichsen; marie.zoga.diederichsen{at}


The case is presented of a woman in her 60s with renal cell carcinoma in a solitary kidney with normal renal function. Because of the solitary kidney status, the management strategy described in acknowledged guidelines was not possible. The patient was treated with standard first-line tyrosine kinase inhibitor followed by percutaneous CT-guided cryoablation. Before and after the procedure the patient had normal kidney function. The treatment resulted in local cancer control, but a bone metastasis developed in the thoracic part of the spine.

  • Cancer intervention
  • Urological cancer
  • Radiology
  • Interventional radiology
  • Renal intervention

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @PiaIben

  • Contributors Drafting the text: MZD, PIP. Sourcing and editing of clinical images: MZD, KSW, PIB. Investigation results: MZD, KSW, CBC, PIP. Critical revision for important intellectual content: MZD, KSW, CBC, PIP. The following authors gave final approval of the manuscript: MZD, KSW, CBC, PIP.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Case reports provide a valuable learning resource for the scientific community and can indicate areas of interest for future research. They should not be used in isolation to guide treatment choices or public health policy.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; externally peer reviewed.